Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (DK2470526) FORBINDELSER OG SAMMENSÆTNINGER SOM PROTEINKINASE-INHIBITORER

Office : Denmark
Application Number: 10748211 Application Date: 27.08.2010
Publication Number: 2470526 Publication Date: 25.08.2014
Grant Number: Grant Date: 25.08.2014
Publication Kind : T3
Prior PCT appl.: Application Number:US2010046930 ; Publication Number: Click to see the data
IPC:
C07D 401/14
A61K 31/506
A61P 35/00
C07D 403/04
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
Applicants: IRM LLC
Inventors: HUANG, Shenlin
Priority Data: 238073 P 28.08.2009 US
313039 P 11.03.2010 US
Title: (DA) FORBINDELSER OG SAMMENSÆTNINGER SOM PROTEINKINASE-INHIBITORER
Abstract:
(EN) The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Also published as:
RSP-2014/0430UAa201203042SG178351IL218084EP2470526DOP2012000051
JP2013503186CN102725283CA2771775EA201200373EP2727918ES2492499
KR1020120062839TN2012000081NZ598924AU2010286569VN30470ID2012/03594
TH140028IN2469/DELNP/2012WO/2011/025927